Just Released: "Singapore Pharmaceuticals Competitive Intelligence Report Q4 2010"

New Healthcare market report from Business Monitor International: "Singapore Pharmaceuticals Competitive Intelligence Report Q4 2010"
Nov. 24, 2010 - PRLog -- The local manufacturing industry is small, at around 20 producers, concentrating mainly on the manufacture of medicaments in retail form, although the government aims to create a stronger biotechnology and pharmaceutical base in the country. Traditional preference for branded products will hamper stronger growth of the domestic industry, but local companies are strong contenders in the global biotechnology sector.

On the contrary, most major pharmaceutical companies have a presence in Singapore, with imports comprising some 80% of medicines used within the healthcare sector. A number operate manufacturing facilities, including Sanofi-Aventis, GlaxoSmithKline (GSK), Merck & Co, Novartis and Schering- Plough, while also being increasingly active in the Singapore-based R&D field.

The number of multinationals with a direct manufacturing presence has risen considerably in recent years, as the government has openly sought investment from foreign pharmaceutical companies. In fact, the country's Economic Development Board (EDB) is targeting a 25% increase in the number of pharmaceutical industry jobs (to 15,000) through to 2015 and hoping to increase the number of production plants from the current 30 to 50. Biomedical manufacturing has been identified as a key area of investment, with production already helping Singapore to weather the recession. In 2008, biomedical exports accounted for 4% of GDP, or around US$7bn.

Pharmaceutical majors, including Pfizer, Novartis and GSK, have invested a total of US$1bn in Singapore between 2004 and 2008. Investments from multinational pharmaceutical companies such as Schering-Plough are assisting Singapore's plans to expand its biomedical industry and increase production to SGD$20bn (US$12bn) by 2010, with domestic companies playing their part through investment and alliance co-operation with foreign partners.

Overall, the growth in research-based sector activity should lead to a greater multinational market presence in both Singapore and across Asia, as multinationals use their Singapore facilities to develop their regional trade. The increase in foreign manufacturing capacity is likely to bring down imports, especially of finished pharmaceutical products. On the other hand, the level of exports is expected to rise, as Singapore's position as a regional operations hub develops, potentially leading to a more favourable balance of trade in pharmaceuticals for Singapore. The selection of the city-state as the Tamiflu (oseltamivir) stockpile further underlines Singapore's status as the regional hub.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/94330_singapore_pharmaceutical...

Report Table of Contents:

Competitive Landscape
- Pharmaceutical Industry
- Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation
- Domestic Pharmaceutical Sector
- Foreign Industry
- Foreign Company Activities
- Traditional Chinese Medicine
Company Profiles
- Indigenous Manufacturers
- Haw Par
- SciGen
- MerLion Pharmaceuticals
- Veredus Laboratories
- Leading Multinationals
- Pfizer
- Novartis
- GlaxoSmithKline
- Sanofi-Aventis
- Merck & Co
- Baxter
Market Attractiveness Analysis
- Market Summary
- Regulatory Regime
SWOT Analysis
- Singapore Pharmaceuticals And Healthcare Industry SWOT
Risk/Reward Rating
- Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q410
- Rewards
- Risks
Business Development Directory

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:***@fastmr.com Email Verified
Tags:Pharmaceutical, Manufacturing, Multinational, Investment, Healthcare, Novartis, Biomedical, Glaxosmithkline, Hub
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share